Kat keyasic Ada sini Ada,PSA nie,APA Yang you nk sebenarnya

Semalam pang kesian kena belasah,mana kata mahu turun 16

Aduh sangkut.... Macam nie la bursa,kecewa

Betul la,khatul comments jatuh

So tomorrow knocked down or get up

Mana yupeetan.kata pakar sangat

Makin turun nie...

Can I know what the meaning of convertible loan

Conversion effect the price up or down...listing tomorrow

How about warrant,gapup to

Menipu je la kau nie..motif

RATIONALE AND BENEFITS FOR THE PROPOSED ACQUISITION
The Proposed Acquisition will provide an initial avenue for KTG Group to venture into transportation
haulage and middle mile logistics business. The new business segment will further enhance KTG
Group’s prospects with the range of services provided, and capabilities possessed by Line Haul as it is
expected to diversify KTG Group’s revenue and earnings base.
The Proposed Acquisition is expected to contribute positively to the earnings and net assets of KTG
Group while reducing dependency on the Group’s existing businesses because Line Haul is an income
generating ready business and already in operation with its existing team of experienced manpower and
resources.
Through Line Haul’s strategic collaboration with LCEL in the last mile delivery segment in which LCEL
engages Line Haul as its haulage service provider and moving forward, Line Haul is still able expand
into sizeable customer base to include other heavy industries and logistics players and B2B customers
from various industries such as cold chain, furniture, machinery, equipment, construction materials.
KTG intends to expand its haulage and transportation services for the middle mile logistics segment. It
intends to adopt a freight sharing services business model for the logistics providers by applying the
pallet network concept. The pallet network concept comprises a hub facilitator which brings together
local haulage partners to be able to offer, often next-day, pick-up and delivery of goods by pallets. Goods
packaged in pallets form are consolidated with other onward shipment of pallets from suppliers in the
same area at the hub facilitator and merge with other pallets destined for same area delivery. This pallet
network concept would enable to increase the vehicle fill rates, reduce number of vehicles, and increase
productivity. In addition, the sharing of loads, heavy vehicles, trucks and facilities is expected to reduce

TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) : NON RELATED PARTY TRANSACTIONS KTG BERHAD (FORMERLY KNOWN AS DWL RESOURCES BERHAD) ("KTG" OR "THE COMPANY") AND ITS SUBSIDIARIES ("KTG GROUP") - PROPOSED ACQUISITION OF THE ENTIRE ISSUED SHARE CAPITAL IN LINE HAUL SDN BHD
KTG BERHAD

Type Announcement
Subject TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS)
NON RELATED PARTY TRANSACTIONS
Description KTG BERHAD (FORMERLY KNOWN AS DWL RESOURCES BERHAD) ("KTG" OR "THE COMPANY") AND ITS SUBSIDIARIES ("KTG GROUP") - PROPOSED ACQUISITION OF THE ENTIRE ISSUED SHARE CAPITAL IN LINE HAUL SDN BHD
The Board of Directors of KTG (“Board”) wishes to announce that the Company had on 18 March 2021 entered into a shares sale agreement (“SSA”) with Line Clear Ventures Holdings Sdn Bhd (formerly known as Line Clear Logistics Holdings Sdn Bhd) (“LCVH” or “Vendor”) [Registration No. 202001016591 (1372911-K)] to undertake the proposed acquisition of 500,000 ordinary shares in Line Haul Sdn Bhd [Registration No. 201901042436 (1351766-K)] (“Line Haul”) (“Sale Shares”), representing the entire issued share capital in Line Haul, from the Vendor for a total cash consideration of RM3 million (“Purchase Consideration”) (“Proposed Acquisition”).

Please refer to the attached for further details.

This announcement is dated 18 March 2021.

Kalau tk mahu Simpan,sell la....happyBuyer jangan dengki la.

Kalau takut dilambung ombak jangan berumah Di tepi pantai...

Relax la bro ..today T3.

Hamid bagi la kata2 sikit

Hamid kau diam la...

COVID-19 vaccine candidate jointly developed by Taiwan's Medigen Vaccine Biologics Corp. and the U.S. National Institutes of Health (NIH) has been authorized to begin human trials, Taiwan's Food and Drug Administration (FDA) said Wednesday (Sept. 30).

This makes it the third vaccine in the country to receive approval.

The MVC-COV1901 vaccine injection received conditional approval for clinical testing on Aug. 31 and was given full approval on Wednesday after Medigen submitted technical documents for additional review, the FDA said.

The first stage of the trial, to test for safety, is expected to take place at National Taiwan University Hospital with about 45 healthy participants, Pan Hsiang-ying (潘香櫻), a specialist in the FDA's Medicinal Products Division, told CNA.

Medigen will become the third company in Taiwan to begin human trials for a COVID-19 vaccine, after Adimmune Corp. and United Biomedical Inc.

After Medigen received conditional approval last month, FDA official Wu Ming-mei (吳明美) said the vaccine is the first targeted at COVID-19 to be jointly developed by Taiwan and the U.S.

According to Wu, the NIH has partnered with two companies -- Medigen and the U.S.-based Moderna Inc. -- to develop two different types of COVID-19 vaccine.

The vaccine developed by Moderna injects messenger RNA into the body, while the one developed by Medigen injects proteins, both of which are aimed at triggering the production of antibodies, Wu said.

Moderna's COVID-19 vaccine has already progressed to a phase 3 clinical study, which evaluates both safety and efficacy, Wu added

REPUBLIKA.CO.ID, TAIPEI -- Badan Pengawas Obat dan Makanan Taiwan (FDA) mengumumkan bahwa calon vaksin Covid-19 yang diproduksi bersama oleh Taiwan dan Amerika Serikat telah memasuki tahap akhir.
Vaksin MVC-COV1901 sedang dikembangkan bersama oleh Medigen Vaccine Biologics Corp. Taiwan dan Institut Kesehatan Nasional AS, dan telah mendapat persetujuan untuk uji coba pada manusia, lansir harian Taiwan News, Kamis (1/10).
Itu adalah calon vaksin ketiga yang diproduksi di negara kepulauan itu. Perusahaan lainnya, Adimmune Corp. dan United Biomedical Inc. juga sedang mengembangkan vaksin Covid-19 lainnya.
Vaksin itu telah menerima persetujuan bersyarat untuk uji klinis pada 31 Agustus, tetapi mendapat persetujuan penuh pada Rabu setelah Medigen menyerahkan dokumen teknis untuk tinjauan tambahan. Pengembang vaksin sedang bekerja untuk uji coba keamanan dengan 45 peserta sehat dan uji coba akan dilakukan di Rumah Sakit Universitas Nasional Taiwan.
Taiwan telah melaporkan 515 kasus virus korona sejak wabah - dengan 423 di antaranya diimpor, termasuk satu dari Indonesia. Sementara itu, tujuh orang tewas akibat Covid-19 di negara itu.

Huitan mana

Semua kaunter ada

Menort diam la

Nexgram pun ada menort

Menort2.. mqtech kau ade... sini pun ada

same shareholder...ms Jaclyn

Meneroka sarung tangan getah...ada kaitan mqtech

Hartawan Macau dilantik pengerusi baharu Inix Technology
4 jam lalu